Evidence map›Paper›PMID 35343996›Full record

ArticleChemical communications (Cambridge, England)2022

Development of small cyclic peptides targeting the CK2α/β interface.

Eleanor L Atkinson, Jessica Iegre, Claudio D'Amore, Paul Brear, Mauro Salvi, Marko Hyvönen, David R Spring

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical communications (Cambridge, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Eleanor L AtkinsonYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, Cambridge, UK. spring@ch.cam.ac.uk.ORCID http://orcid.org/0000-0003-2498-2486
Jessica IegreYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, Cambridge, UK. spring@ch.cam.ac.uk.ORCID http://orcid.org/0000-0002-9074-653X
Claudio D'AmoreDepartment of Biomedical Sciences, University of Padova, Padova, Italy. mauro.salvi@unipd.it.
Paul BrearDepartment of Biochemistry, University of Cambridge, Tennis Court Road, CB2 1GA, Cambridge, UK. mh256@cam.ac.uk.ORCID http://orcid.org/0000-0002-4045-0474
Mauro SalviDepartment of Biomedical Sciences, University of Padova, Padova, Italy. mauro.salvi@unipd.it.ORCID http://orcid.org/0000-0003-3448-6048
Marko HyvönenDepartment of Biochemistry, University of Cambridge, Tennis Court Road, CB2 1GA, Cambridge, UK. mh256@cam.ac.uk.ORCID http://orcid.org/0000-0001-8683-4070
David R SpringYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, Cambridge, UK. spring@ch.cam.ac.uk.ORCID http://orcid.org/0000-0001-7355-2824
University of Cambridge · GBUniversity of Padua · IT

Funding

Wellcome Trust
6 · The paper itself

Abstract

In this work, an iterative cycle of enzymatic assays, X-ray crystallography, molecular modelling and cellular assays were used to develop a functionalisable chemical probe for the CK2α/β PPI. The lead peptide, P8C9, successfully binds to CK2α at the PPI site, is easily synthesisable and functionalisable, highly stable in serum and small enough to accommodate further optimisation.

Indexed as

Casein Kinase IIPeptides, CyclicCrystallography, X-RayModels, MolecularPeptidesCasein Kinase IIPeptidesPeptides, Cyclic

Identifiers

PMID35343996
PMCPMC9004346
OpenAlexW4220924331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.